Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept

Archives of Dermatology

Volumn 140, Issue 12, 2004, Pages 1539-1540

  Querfeld, Christiane ^b   Guitart, Joan ^b   Kuzel, Timothy M ^b   Rosen, Steven ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CD40 ANTIGEN; ETANERCEPT; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; PSORALEN; RETINOID; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACTINIC RETICULOID; ADULT; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; ERYTHRODERMA; FEMALE; FLOW CYTOMETRY; HUMAN; IDIOPATHIC DISEASE; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; MALE; MOLLUSCUM CONTAGIOSUM; NOTE; PRIORITY JOURNAL; PRURITUS; REMISSION; SEZARY SYNDROME; SKIN BIOPSY; SKIN LYMPHOMA; STEROID THERAPY; T CELL LYMPHOMA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VISUAL ANALOG SCALE;

ADULT; DERMATITIS, EXFOLIATIVE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PRURITUS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 10344226749     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.12.1539     Document Type: Note

References (4)

1. Greaves MW, Wall PD. Pathophysiology of itching. Lancet. 1996;348:938-940.
2. Reinhold AM. New indications of treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci. 2003;325:75-92.
3. Kurzrock R, Tsimberidou AM, Giles FJ, Duvic M. Pilot study of recombinant human soluble tumor necrosis factor receptor fusion protein etanercept in patients with relapsed cutaneous T-cell lymphomas. In: Proceedings of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2374.
4. Guitart J, Kennedy SR. Chmiel JS, et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol. 2001;28;174-183.